NeuroKaire vs Sequentify
NeuroKaire vs Sequentify, compared side by side on 19 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: NeuroKaire is on 56/100 and Sequentify on 48/100.
Where each one leads
NeuroKaire
- our overall score: 56/100 against 48/100
- domain rating: 8/100 against 7/100
- headcount: 36 against 7
- funding raised: $27.3M against $7.0M
- LinkedIn following: 9,619 against 1,377
Sequentify
- agent readiness: 41/100 against 21/100
At a glance
| Measure | NeuroKaire | Sequentify |
|---|---|---|
| What it is | Personalized medical testing tool to optimize drug therapy for depression. | Making targeted DNA sequencing as common, fast, and affordable as a blood test. |
| Category | Neuroscience, Biotech, Mental Health, Drug Therapy | Healthcare, Life Sciences, Next Generation Sequencing, HealthTech |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2017 | 2021 |
| Headquarters | Tel Aviv, Israel | San Francisco, United States |
| Status | Active | Active |
Size, funding and growth
| Measure | NeuroKaire | Sequentify |
|---|---|---|
| Employees | 36 | 7 |
| Headcount growthLast 12 months | Not published | -10.0% |
| Total funding | $27.3M | $7.0M |
| Latest round | Grant | Seed |
| LinkedIn followers | 9,619 | 1,377 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | NeuroKaire | Sequentify |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 56/100 | 48/100 |
| Traction | 53/100 | 43/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 34/100 | 25/100 |
| Quality | 58/100 | 48/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | D (41/100) |
| Domain ratingLink authority, 0-100 | 8/100 | 7/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | NeuroKaire | Sequentify |
|---|---|---|
| CMS | Not detected | Wix |
| Open source | No | Yes |
NeuroKaire vs Sequentify: common questions
Which is better, NeuroKaire or Sequentify?
On our 0-100 score NeuroKaire rates higher (56/100 against 48/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 19 data points above: read the rows that match what you are buying for.
How do NeuroKaire and Sequentify compare on the numbers?
NeuroKaire leads on our overall score (56/100 against 48/100), domain rating (8/100 against 7/100), headcount (36 against 7), funding raised ($27.3M against $7.0M), LinkedIn following (9,619 against 1,377). Sequentify leads on agent readiness (41/100 against 21/100).
Read the full NeuroKaire review and pricing or the Sequentify review and pricing. You can also browse other NeuroKaire alternatives we track.